BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

New evidence hints that statins may protect a wider range of people with type 2 diabetes than previously assumed. A major ...

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers ...

(HealthDay News) — Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated fat intake can reduce mortality and major cardiovascular ...

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

The Adriatic diet represents a regional Mediterranean dietary pattern rich in olive oil, plant foods, and fish that supports ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Researchers from Philadelphia-based University of Pennsylvania’s Leonard Davis Institute of Health Economics recently found that coronary artery bypass grafts are the most lucrative cardiology ...

Part of the challenge lies with identifying otherwise healthy individuals — especially women — who lack standard modifiable ...